Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer

Award Number: R42CA203456
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/07/2016
PERIOD OF PERFORMANCE END DATE: 03/31/2021

Group Awards By:

View Award Description

Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer - Recent FDA approvals of ipilimumab, nivolumab, and pembrolizumab, which target checkpoint receptors cytotoxic T lymphocyte associated antigen-4 (CTLA-4) and programmed death-1 (PD-1), have ushered in a new era of cancer immunotherapy in metastatic melanoma. Despite unprecedented overall survival benefits with combination therapy, the incidence of complete responses are only 12-22%, immune-related adverse events (irAEs) are increased, and the cost of treatment is approaching $275,000 per patient per year. As such, cost-effective approaches to improve the safety and effectiveness of checkpoint blockade for not only metastatic melanoma, but also for more genetically stable solid tumors are needed. Cell adhesion integrins VLA-4 and LFA-1 are required for efficient antigen presentation, trafficking, and tumoricidal activity of effector cells. These integrin receptors are clinically validated therapeutic targets in autoimmune disease; inhibitors such as natalizumab decrease T-cell activation and migration. Conversely, we have discovered small molecule integrin agonists, eg, 7HP349, that may increase the efficiency of the immune response against solid tumors. This approach could be particularly useful when combined with immune checkpoint blockade. Completed phase I studies have demonstrated that 7HP349 can significantly enhance the anti-tumor activity of anti-CTLA- 4, anti-PD-1, and anti-4-1BB antibodies in animal models of melanoma and carcinoma. Toxicity studies have demonstrated the compound to be safe, even when administered at doses up to 80-fold higher that it’s therapeutic dose. Based on this success, our current phase II effort is centered around in vivo testing of oral administration of 7HP349 in the B16-BL6 melanoma model, mechanistic studies to guide biomarker development, including the effects of 7HP349 on T effector cell biodistribution (Specifc Aim 1), GLP IND- enabling studies of toxicity in rodent and non-rodent species, including radiolabeled ADME (Specific Aim 2), and an iterative synthetic chemistry approach to further optimize drug like characteristics of our lead candidate 7HP349 (Specific Aim 3). All work proposed will be consistent with FDA guidelines outlined in “Guidance for Industry: S9 Nonclinical evaluation of anticancer pharmaceuticals.”


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2019	7 HILLS PHARMA LLC	2126 SHERIDAN ST	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	000	3	6/4/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $1,001,898 )
2019	2019	7 HILLS PHARMA LLC	8285 EL RIO STE 130	HOUSTON	TX	77054	HARRIS	USA	Cancer Treatment Research	001	3	3/29/2019	NON-COMPETING CONTINUATION	$1,001,898
2019	2018	7 HILLS PHARMA LLC	8285 EL RIO STE 130	HOUSTON	TX	77054	HARRIS	USA	Cancer Treatment Research	000	2	11/6/2018	COMPETING CONTINUATION	$0
														Subtotal = $1,001,898

Issue Date FY: 2018 ( Subtotal = $999,501 )
2018	2018	7 HILLS PHARMA LLC	2126 SHERIDAN ST	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	001	2	9/5/2018	COMPETING CONTINUATION	$1,400
2018	2018	7 HILLS PHARMA LLC	2126 SHERIDAN ST	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	000	2	4/9/2018	COMPETING CONTINUATION	$998,101
														Subtotal = $999,501

Grand Total All Awards = $2,001,399

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer

Award Number: R42CA203456

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/07/2016

PERIOD OF PERFORMANCE END DATE: 03/31/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer